Video

Aspirin: Too Much of a Good Thing?

Author(s):

HCPLive staff

Over the counter or on a physician's advice, millions of people take aspirin prophylactically. Cardiologist Jeffrey Berger, MD, from NYU Langone Medical Center in Manhattan, discusses the pitfalls and potential benefits of daily aspirin.

Aspirin can prevent heart attacks. But it carries risks and new studies show it is being used inappropriately. HCPLive went to NYU Langone Medical Center in Manhattan to discuss the issue with cardiologist Jeffrey Berger, MD

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM | Image Credit: Radcliffe Cardiology
Related Content
Children with IBD Respond Well to the Pfizer COVID-19 Vaccination, with Arthur Kastl, MD
November 21st 2024

Children with IBD Respond Well to the Pfizer COVID-19 Vaccination, with Arthur Kastl, MD

Chelsie Derman
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
November 21st 2024

Diabetes Dialogue: News and Updates in Diabetes at AHA 2024

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Steve Nissen, MD | Credit: Cleveland Clinic
November 18th 2024

Zerlasiran 60-Week Data Reinforce Lp(a) Reductions Observed in ALPACAR-360

Patrick Campbell
Kidney Compass default thumbnail with podcast logo and headshots of hosts Brendon Neuen and Shikha Wadhwani.
October 28th 2024

Kidney Compass: FLOW Insights from Kidney Week 2024, with Katherine Tuttle, MD

Brendon Neuen, MBBS, PhD Shikha Wadhwani, MD, MS
Bumetanide Nasal Spray Equivalent to Oral, IV Forms for Heart Failure| Image Credit: American Heart Association
November 18th 2024

Bumetanide Nasal Spray Equivalent to Oral, IV Forms for Heart Failure

Connor Iapoce
Sacubtril/Valsartan Lowers Risk of Cardiotoxicity Linked to Chemotherapy | Image Credit: American Heart Association
November 18th 2024

Sacubtril/Valsartan Lowers Cardiotoxicity Risk Linked to Chemotherapy

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.